Results 1 to 3 of 3
Page 1 of 1
TypeTitleAuthor(s)YearViews
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)Yau, TCC; Sukeepaisarnjaroen, W; Chao, Y; Yen, CJ; Lausoontornsiri, W; Chen, PJ; Sanpajit, T; Lencioni, R; Camp, AC; Cox, DS; Kallender, H; Ottesen, LH; Poon, RTP201249
 
A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)Yau, TCC; Sukeepaisarnjaroen, W; Chao, Y; Yen, CJ; Lausoontornsiri, W; Chen, PJ; Sanpajit, T; Lencioni, R; Camp, A; Kallender, H; Ottesen, LH; Poon, RTP2011117
 
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)Yau, T; Yen, CJ; Chen, PJ; Chau, Y; Lencioni, R; Kallender, H; Ottesen, LH; Poon, RTP2011252
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download